ArticleAmerican journal of cancer research2024
LncRNA SLC16A1-AS1 participates in the initiation and progression of colorectal cancer by regulating MAP3K9 expression through targeting miR-515-5p.
Article in American journal of cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- CircASH1L inhibits ferroptosis and enhances cisplatin resistance by sponging miR-515-5p to regulate cell cycle-related CDCA7/RRM2 in ovarian cancer cells.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the role of long non-coding RNA (lncRNA) SLC16A1-AS1 in the initiation and progression of colorectal cancer (CRC).
methodsCell viability was tested using Cell Counting Kit-8 (CCK-8). Cell invasion and migration were evaluated using Transwell assays, and apoptosis was determined by flow cytometry. Gene expression was tested by qRT-PCR or Western blot. The targeting relationship between miR-515-5p and MAP3K9 was verified using bioinformatics tools, RNA immunoprecipitation (RIP) experiments, and dual-luciferase reporter assays.
resultsBoth lncRNA SLC16A1-AS1 and MAP3K9 were upregulated in CRC cells, while miR-515-5p expression was downregulated. Overexpression of miR-515-5p and silencing of lncRNA SLC16A1-AS1 inhibited CRC cell proliferation, suppressed cell invasion and migration, and promoted cell apoptosis. The targeting relationship between lncRNA SLC16A1-AS1 and miR-515-5p, as well as between MAP3K9 and miR-515-5p, were confirmed by bioinformatics, RIP assays, and luciferase reporter assays.
conclusionlncRNA SLC16A1-AS1 contributes to the initiation and progression of CRC by modulating miR-515-5p to regulate MAP3K9 expression, providing potential insights for CRC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.